Inhibiteurs de la résorption osseuse et risque d’ostéonécrose des mâchoires (ONM)

Prescription of bone resorption inhibitors implies a thorough evaluation of associated risks weighed against expected benefits. Although quite infrequent but highly debilitating, medication-related osteonecrosis of the jaw (MRONJ) is the most highly feared complication of such treatments, both by patients and some healthcare professionals. A concerted multiprofessional approach, primary prevention via systematic oral health examination as whenever possible, but also regular follow-up with an oral health professional, could all help limit the risk of MRONJ, increase patient adherence to treatment and improve the overall quality of care.